Effects of perzinfotel on the minimum alveolar concentration of isoflurane in dogs.
OBJECTIVE
To determine the effect of IV administration of perzinfotel on the minimum alveolar concentration (MAC) of isoflurane in dogs. Animals-6 healthy sexually intact male Beagles.


METHODS
Dogs were instrumented with a telemetry device that permitted continuous monitoring of heart rate, arterial blood pressure, and body temperature. Dogs were anesthetized with propofol (4 to 6 mg/kg, IV) and isoflurane for 30 minutes before determination of MAC of isoflurane. Isoflurane MAC values were determined 4 times, separated by a minimum of 7 days, before and after IV administration of perzinfotel (0 [control], 5, 10, and 20 mg/kg). Bispectral index and percentage hemoglobin saturation with oxygen (SpO(2)) were monitored throughout anesthesia.


RESULTS
Isoflurane MAC was 1.32 +/- 0.14%. Intravenous administration of perzinfotel at 0, 5, 10, and 20 mg/kg decreased isoflurane MAC by 0%, 24%, 30%, and 47%, respectively. Perzinfotel significantly decreased isoflurane MAC values, compared with baseline and control values. The bispectral index typically increased with higher doses of perzinfotel and lower isoflurane concentrations, but not significantly. Heart rate, body temperature, and SpO(2) did not change, but systolic, mean, and diastolic arterial blood pressures significantly increased with decreases in isoflurane MAC after administration of perzinfotel at 10 and 20 mg/kg, compared with 0 and 5 mg/kg.


CONCLUSIONS
IV administration of perzinfotel decreased isoflurane MAC values. Improved hemodynamics were associated with decreases in isoflurane concentration.
Kushiro
Tokiko
T
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.
Wiese
Ashley J
AJ
Eppler
Mark C
MC
Muir
William W
WW
D000700:Analgesics / Q000493:pharmacokinetics / Q000494:pharmacology*; D000769:Anesthesia, Inhalation / Q000662:veterinary; D018685:Anesthetics, Inhalation / Q000493:pharmacokinetics*; D000818:Animals; D053961:Azabicyclo Compounds / Q000493:pharmacokinetics / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D007530:Isoflurane / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D063065:Organophosphonates / Q000493:pharmacokinetics / Q000494:pharmacology*; D011650:Pulmonary Alveoli / Q000378:metabolism*
D000700:Analgesics; D018685:Anesthetics, Inhalation; D053961:Azabicyclo Compounds; D063065:Organophosphonates; D007530:Isoflurane; C110623:EAA-090